Two AI Labs Took 43% of H1's Venture Dollars. A $500M Early-Stage Fund Just Closed Anyway — Oversubscribed, at Hard Cap.
In a half-year when two companies took 43 cents of every venture dollar invested anywhere on earth, a fund that will never write a check to either of them just closed oversubscribed, at hard cap, nearly double the size of its predecessor.
B Capital closed Ascent Fund III at a $500 million hard cap on July 6 — oversubscribed, targeting Seed through Series B rounds in healthcare, enterprise software, energy, and frontier technology across North America and Asia. Its previous early-stage vehicle, closed in 2022, raised $254 million. LP demand for this fund nearly doubled in four years, across the exact period the "venture capital is dying outside of AI mega-rounds" narrative was supposed to be starving funds like this one of appetite.
The concentration numbers are real and worth restating: Crunchbase's H1 2026 close put global venture funding at a record $510 billion, with OpenAI and Anthropic alone absorbing $217 billion of it — 43% of every dollar invested, across every sector, every stage, anywhere in the world. That statistic gets repeated in every quarterly recap as proof the venture middle is being crowded out. B Capital's raise complicates that read without contradicting it.
What it suggests instead is that capital is consolidating on two separate axes at once. The AI-lab concentration story is about where startup dollars land. There's a second, quieter consolidation happening at the fund level: five VC firms captured 73% of all LP capital raised in Q1 2026. Early-stage capital isn't disappearing — it's increasingly flowing through a shrinking number of large, brand-name multi-stage platforms rather than being spread across the broader base of fund managers who used to compete for that same LP capital.
The sector mix inside Ascent Fund III is worth noting on its own terms. Healthcare, enterprise software, energy, and frontier tech — not a single-sector AI mandate — suggests LPs still want diversified thematic exposure even as they concentrate that exposure into fewer, larger relationships. They haven't stopped believing in a broad venture thesis. They've gotten more selective about who gets trusted to execute it.
For founders building at the application layer — fintech, agentic finance, vertical AI outside the foundation-model tier — the read-through isn't "there's no capital." It's that the entry point has narrowed. A single B Capital-sized platform check now functionally replaces what might have been three or four separate relationships with smaller, more specialized funds a few years ago. Access to capital hasn't closed. Access to capital allocators has.
The concentration numbers that dominate every quarterly VC recap are accurate and, on their own, incomplete. Capital is consolidating at the startup level and at the fund level simultaneously, for different reasons, and both funnels are narrowing into fewer hands at the same time. Whether that's a temporary flight to size or a permanent restructuring of how early-stage capital gets allocated is the more interesting question the $500 million headline doesn't answer.
| Metric | Value |
|---|---|
| Global H1 2026 venture funding | $510 billion (Crunchbase) |
| Share to OpenAI + Anthropic alone | 43% ($217B) |
| B Capital Ascent Fund III | $500M hard cap, oversubscribed |
| B Capital Fund II (2022) | $254M |
| Share of Q1 LP capital to top 5 VC firms | 73% |
Frequently asked questions
What is B Capital's Ascent Fund III?
It's B Capital's third early-stage venture fund, closed July 6, 2026 at a $500 million hard cap after being oversubscribed, targeting Seed through Series B investments in healthcare, enterprise software, energy, and frontier technology across North America and Asia.
How does this fund close compare to the AI funding concentration story?
It closed in the same half-year that OpenAI and Anthropic alone absorbed 43% of a record $510 billion in global venture funding, showing that LP demand for early-stage, non-AI-labeled risk persisted even as headline dollars concentrated in a handful of frontier AI labs.
Is early-stage venture capital broadly healthy despite AI concentration?
Partially — LP capital itself is also consolidating at the fund level, with five VC firms capturing 73% of Q1 2026 LP commitments, so early-stage capital increasingly flows through fewer, larger, brand-name platforms rather than being evenly distributed across the fund manager base.